Acute Myeloid Leukaemia and Myelodysplastic Syndrome Gene Panels (Pilot - Not Accredited)


** New for 2019 - Myelodysplastic Syndrome related changes will now be included in this programme. 


The programme is primarily aimed at participants using Next Generation Sequencing (NGS) panels to diagnose and prognosticate Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). One lyophilised sample from an AML or MDS patient or cell line will be issued and participants will be expected to test the sample with their in-house panels and report any pathogenic intragenic and/or regulatory element changes such as point mutations, small insertion, deletion and duplications events. Participants will not be requested to report larger changes affecting genome architecture or copy number changes (>50kb).


Please note, the number of samples issued per distribution will decreased from two to one in 2018/19. 


Pre issue testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.

To register for this programme, please click here.
Example Acute Myeloid Leukaemia Gene Panels (Not Accredited) Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
AML GP 171802 Report Example.pdf
Adobe Acrobat document [986.2 KB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 15/10/2020 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).